Today, GLP-1 drugs account for about 15% of monthly revenue in practices that offer them, and approximately 40% of patients receiving GLP-1 treatments in 2024 were new to those practices
Praga, M
Placental passage of metformin in women with polycystic ovary syndrome
The wide range of health benefits associated with weight loss among obese individuals has led researchers to investigate different mechanisms and identify pharmacological targets to treat obesity
This process of shared decision-making involves discussing your weight loss goals, your expectations for treatment, the potential benefits and risks, and how the treatment will fit into your overall health plan
The first study, conducted in male mice, found that exenatide treatment did not significantly alter morphine-conditioned place preference, intravenous self-administration of the short-acting synthetic opioid remifentanil, morphine-induced locomotor activity, or the somatic signs of morphine withdrawal
